Lac-Phe
Lactoylphenylalanine, or Lac-Phe, is an N-lactoyl-amino acid metabolite produced by mammals and microorganisms.
≈ 3 min read
Lac-Phe. encyclopegia.org, snapshot enwiki-001377082013. /a/lac-phe
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lactoylphenylalanine, or Lac-Phe, is an N-lactoyl-amino acid metabolite produced by mammals and microorganisms. In humans, levels are increased by intense exercise and in the inborn error of metabolism phenylketonuria.
In mice, high levels of Lac-Phe in the blood cause a decrease of food intake and in humans, its production has been shown to correlate with adipose tissue loss during an endurance exercise intervention. In mammals it is created from (S)-lactate and L -phenylalanine by the cytosol nonspecific dipeptidase (CNDP2) protein. It is classified as N-acyl-alpha-amino acid and pseudodipeptide.
It has also been reported that as an additive, N- L -lactoyl phenylalanine improves the taste of food, conferring an umami flavor. It is found naturally in significant amounts in some traditional Chinese fermented foods such as preserved pickles and soy sauce, and in Parmigiano-Reggiano cheese.
Oral intake of Lac-Phe does not have anti-obesity effects in mice, though intraperitoneal injection does reduce food intake and weight gain. Activity dependent cell labeling indicates Lac-Phe activated neural populations in the hypothalamus and brainstem. Lac-Phe was discovered as a hormone at Stanford University in 2022.
It is released during intense exercise and after eating and reduces appetite and obesity in animals. Besides metabolic effects, Lac-Phe has also been found to produce anxiolytic-like effects in rodents, which were associated with dopaminergic and serotonergic signaling as well as reduced hippocampal cytokine expression.
Lac-Phe itself has poor pharmacokinetic properties, for instance a short duration. A synthetic alternative known as ENV-308 suitable for once-daily oral administration is described as an exercise mimetic and is under formal clinical development as of 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377082013 under CC BY-SA 4.0; modifications have been made.